Actively Recruiting
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Led by Li Lab,MD · Updated on 2025-04-23
100
Participants Needed
2
Research Sites
147 weeks
Total Duration
On this page
Sponsors
L
Li Lab,MD
Lead Sponsor
X
Xin Hua Hospital of Zhejiang Province
Collaborating Sponsor
AI-Summary
What this Trial Is About
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals. With the prevalence of obesity and type 2 diabetes, the morbidity and incidence of MAFLD have been increasing globally, particularly in China. MAFLD and metabolic syndrome as well as type 2 diabetes are mutually causal, jointly promoting the incidence of atherosclerotic cardiovascular disease, chronic kidney disease, liver decompensation, and malignant tumors such as hepatocellular carcinoma. MAFLD has become an increasingly severe public health issue in China. Effective clinical interventions for MAFLD patients are of great public health significance for the prevention of terminal diseases. Cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra are traditional Chinese medicinal herbs that have demonstrated significant effectiveness in improving metabolic diseases. Cynara scolymus contains polyphenols, flavonoids, terpenes, and other substances, possessing antioxidant, anti-aging, anti-tumor, anti-microbial, antihypertensive, and kidney-tonifying properties. Silybum marianum belongs to the Compositae family and has the effects of clearing heat and detoxifying, soothing the liver, and promoting bile flow. The active ingredient of silybum marianum is silymarin, a flavonoid compound, which has antioxidant and anti-hepatic fibrotic effects, protecting hepatocytes from damage by free radicals and promoting hepatocyte regeneration and repair. Curcuma longa is a flowering plant of the zingiberaceae family, and its active ingredient curcumin has multiple functional properties such as anti-tumor, anti-inflammatory, hypoglycemic, and antioxidant activities. Glycyrrhiza glabra is one of the commonly used medicinal plants, possessing the effects of clearing heat and detoxifying, tonifying the spleen and benefiting qi, nourishing the lungs, and resolving phlegm. Its main active ingredients include triterpenoid saponins, flavonoids, and polysaccharides, which exhibit various pharmacological effects such as antioxidant, immunoregulatory, antiviral, and anti-tumor activities. At the human population level, there is currently no research on the combined intervention of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra in patients with MAFLD. Therefore, this study intends to conduct a randomized controlled double-blind trial to explore the effects of the combined application of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra on liver function, liver fat content, glucose and lipid metabolism, and other aspects in patients with MAFLD, in order to clarify the health improvement effects of this combined intervention in patients with MAFLD and provide population-based evidence and strategies for health promotion in this patient group.
CONDITIONS
Official Title
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with metabolic-associated fatty liver disease with mild to moderate fatty liver
- Aged between 18 and 65 years, any gender
- No use of liver-protecting medications in the past 3 months
- Voluntarily agree and sign informed consent to participate in all study visits and treatments
You will not qualify if you...
- Excessive alcohol consumption or unclear alcohol use in the past 12 months (≥210g/week for males, ≥140g/week for females)
- Pregnant, breastfeeding, or planning pregnancy within 3 months
- Known allergies or reactions to ingredients in the study products
- Previous or current use of liver-protecting products containing study herbs
- Other liver diseases like autoimmune liver disease, viral hepatitis, liver fibrosis, cirrhosis, drug-induced liver disease, Wilson's disease
- Current treatment for obesity, hypertension, or diabetes with related medications
- Diseases causing fatty liver such as total parenteral nutrition or congenital lipoatrophic diabetes
- Long-term use of drugs known to cause fatty liver or inflammation (e.g., amiodarone, methotrexate, tamoxifen, glucocorticoids)
- Severe cardiovascular, cerebrovascular diseases, or kidney failure
- Unstable weight or metabolism in 6-8 weeks before randomization (weight change >5% or rapid loss >1.6 kg/week)
- Cancer history in past 5 years except localized skin basal cell carcinoma
- Immunosuppression or immunodeficiency disorders, or current immunosuppressive treatment
- Chronic diseases like asthma, epilepsy, thyroid disorders or related treatments
- History of drug abuse
- Antibiotic use in past month
- Participation in other intervention studies in past 3 months or receiving other treatments during study
- Other factors judged by researchers to affect participation or follow-up, such as unstable living or work environment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Select..., China, 310053
Actively Recruiting
2
Zhejiang Xinhua Hospital
Hangzhou, Zhejiang, China, 310005
Actively Recruiting
Research Team
Q
Qingling Huang
CONTACT
K
Kaixin Pan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here